Breaking News

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals

Thursday, June 16th @ 10:30 a.m. ET

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (World NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a medical-stage biopharmaceutical organization developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic products candidate for the acute remedy of migraine, these days introduced that it will host a Essential Opinion Leader (KOL) webinar on the acute treatment method of migraine, DHE, and STS101 on Thursday, June 16, 2022 at 10:30 a.m. ET.

The webinar will function shows from KOLs Amaal J. Starling, M.D., from the Mayo Clinic Higher education of Drugs and Science, and Stewart J. Tepper, M.D., from the Geisel Faculty of Drugs at Dartmouth University, who will talk about the current therapy landscape and unmet professional medical have to have in dealing with clients struggling from migraines.

Satsuma’s STS101, dihydroergotamine nasal powder, will be reviewed as a novel investigational therapeutic solution applicant for the acute treatment of migraine. John Kollins, Satsuma’s President & CEO, will supply a enterprise update.

A dwell query and solution session will stick to the highlighted presentations by Vital View Leaders. To RSVP for the KOL webinar, you should register in advance of time by clicking below.
A replay will be obtainable in the Activities & Shows part of the Satsuma internet site.        

Amaal J. Starling, M.D. is an Affiliate Professor of Neurology in the Mayo Clinic College or university of Medicine and Science. She joined Mayo in 2012 and is at the moment a board-certified Marketing consultant inside of the Division of Neurology. She is presently the Clinical Follow Chair of the Division of Headache the Affiliate Method Director for the Headache Medicine Fellowship and is Software Director for the Transitional 12 months Residency System in the Mayo Clinic College or university of Medicine and Science – Arizona Campus.

Dr. Starling obtained her M.D. degree from Drexel University College or university of Medication in Philadelphia. She concluded a Transitional Calendar year Residency, a Neurology Residency, and a Headache Fellowship at the Mayo Clinic School of Medication in Scottsdale, Arizona.

She is a Fellow of the American Academy of Neurology and the American Headache Society. She is an lively member American Professional medical Association and the American Discomfort Society. Dr. Starling serves on the advisory boards of the Worldwide Concussion Society (ICS), NeurologyLive, the NDPH Study Basis, the United Council for Neurologic Subspecialties, Alliance for Headache Problems Advocacy, and the American Headache Modern society. In addition, she has served as the Co-Chair of the American Headache and Migraine Affiliation, Chair of the New Investigator and Trainee Unique Desire Portion and Electronic Media Committee of the AHS. She is the present-day Advocacy Committee Chair of the AHS. She has been an invited speaker to a lot of international, countrywide, and regional meetings and has been a perennial speaker at the AHS Once-a-year Conference in Scottsdale, Arizona. Her lots of honors include the AHS Over and Beyond Award for Assistance, Manfred D. Muenter Award for Excellence in Scientific Neurology, the American Academy of Neurology Annual Meeting Residency Scholarship, the 2012 Spirit of Mayo Clinic Award, and the Mayo Brothers Distinguished Fellowship Award.

Dr. Starling has various peer-reviewed publications and abstracts similar to her fields of fascination which involve migraine, concussion, posttraumatic headache, trigeminal autonomic cephalalgias, secondary problems, telemedicine and teleconcussion, and resident schooling. She is an active participant and member of several instructional and departmental committees in Mayo Clinic.

Stewart J. Tepper, M.D., is Professor of Neurology at the Geisel School of Drugs at Dartmouth in Hanover, New Hampshire. He is Director of the Dartmouth Headache Middle in the Department of Neurology of Dartmouth-Hitchcock Health-related Centre, Lebanon, New Hampshire. Dr. Tepper acquired his undergraduate diploma cum laude in the review of the nervous process/psychobiology from Yale College or university, New Haven, Connecticut, and attended Cornell University Health-related Faculty in New York Town. He done his Neurology residency at the Harvard Longwood Region system, Boston, Massachusetts, and has been board qualified in Headache Medication because 2006.

Dr. Tepper was Director of the Scottsdale Headache Symposium CME study course of the American Headache Modern society from 2008 to 2020. He was Editor-in-Chief of the journal Headache Currents and Associate Editor for the journal Headache from 2012-2020. He has released far more than 450 peer-reviewed manuscripts, editorials, chapters, and textbooks on Headache Medication. Dr. Tepper serves on the Govt Board of Administrators and is the Corporate Liaison for the American Headache Modern society. He serves on the AHS Training, Exhibits, and Finance Committees. He also serves on the Governance Committee and Board of Administrators of the American Migraine Foundation.

About Satsuma Prescribed drugs and STS101

Satsuma Prescribed drugs is a medical-stage biopharmaceutical organization creating a novel therapeutic products, STS101, for the acute therapy of migraine. STS101 is a distinctive and proprietary nasal powder formulation of the perfectly-recognized anti-migraine drug, dihydroergotamine mesylate (DHE), administered through Satsuma’s proprietary nasal delivery machine.  STS101 is developed to supply sizeable gains compared to current acute therapies for migraine, together with the combination of swift and handy self-administration and other medical rewards, that latest DHE liquid nasal spray goods and injectable dosage kinds lack. Satsuma’s dry powder DHE formulation has demonstrated quick absorption, immediate achievement of significant DHE plasma concentrations which Satsuma believes is important for early efficacy, and sustained DHE plasma amounts in excess of time with lower dose-to-dose variability. STS101 also now incorporates an improved 2nd-technology nasal shipping unit designed to give a lot more regular nasal dosing, irrespective of person administration method. DHE has extensive been suggested in released migraine treatment method recommendations as a 1st-line acute therapy selection for migraine and has considerable strengths compared to other anti-migraine therapies for many individuals. Nonetheless, negatives of recent DHE liquid nasal spray and injectable products and solutions, including invasive and burdensome administration and/or sub-exceptional clinical performance, have limited the prevalent use of DHE. That includes an effortless-to-carry and straightforward-to-use dosage type, STS101 is designed to conquer these shortcomings and deliver individuals an improved therapeutic option for acutely managing migraines that continually delivers strong medical efficiency.

Satsuma is headquartered in South San Francisco, California with functions in both equally California and Study Triangle Park, North Carolina. For even further information, be sure to stop by

Investor AND Company CONTACTS:

Corey Davis, PhD
LifeSci Advisors, LLC
[email protected]

Tom O’Neil, Main Economic Officer
Satsuma Prescription drugs, Inc.
[email protected]